The company credited its molecular diagnostics and international businesses as drivers of new growth.
The company, which beat analyst estimates on both the top and bottom lines, said completed Cologuard test volume rose 149 percent to 135,000 tests.
The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit.
The company has contracted IPS Genomix to distribute the SelectMDx test in Lebanon, Egypt, the UAE, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan.
The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.
The company also announced that it has received New York State Department of Health conditional approval for three women's health molecular diagnostic tests.
The proceeds from the offering will be used to fund the expansion of commercialization activities for the firm's colon cancer test, Cologuard.
The company said the number of lives now covered for EndoPredict has gone up to 109 million.
The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.